GlobeNewswire

European Commission approves Ponvory (ponesimod) for the treatment of adults with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features

Share

Allschwil, Switzerland – May 25, 2021
Idorsia Ltd (SIX: IDIA) was informed by the Janssen Pharmaceutical Companies of Johnson & Johnson that the European Commission (EC) has approved Ponvory™▼(ponesimod) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.

Idorsia and Actelion Pharmaceuticals Ltd, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, have entered into a revenue-sharing agreement in respect to ponesimod. Under the terms of the revenue-sharing agreement, Idorsia is entitled to receive quarterly payments of 8% of the net sales of ponesimod products from Actelion.

For further details please read the full announcement from Janssen available here.

Notes to the editor

▼Adverse events should be reported. This medicinal product is subject to additional monitoring and it is therefore important to report any suspected adverse events related to this medicinal product.

About Idorsia
Idorsia Ltd is reaching out for more – We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core.

Headquartered near Basel, Switzerland – a European biotech-hub – Idorsia is specialized in the discovery, development and commercialization of small molecules to transform the horizon of therapeutic options. Idorsia has a broad portfolio of innovative drugs in the pipeline, an experienced team of professionals covering all disciplines from bench to bedside, state-of-the-art facilities, and a strong balance sheet – the ideal constellation to translate R&D efforts into business success.

Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 900 highly qualified specialists dedicated to realizing our ambitious targets.

For further information, please contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
investor.relations@idorsia.com
media.relations@idorsia.com
www.idorsia.com

The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Karolinska Developments portföljbolag Aprea Therapeutics uppnår primärt utfallsmått i kombinationsterapi av AML med eprenetapopt17.6.2021 10:25:55 CEST | Pressemelding

STOCKHOLM, SVERIGE 17 juni 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Aprea Therapeutics rapporterar positiva resultat från en pågående fas 1/2-studie av bolagets läkemedelskandidat eprenetapopt i kombination med venetoklax och azacitidin i patienter med TP53-muterad akut myeloisk leukemi, AML. Studieresultaten visar att behandlingen uppnår studiens förutbestämda primära effektmått med fullständig remission i 37% av de utvärderade fallen. Studieresultaten baseras på en analys av 30 evaluerbara patienter där fullständig remission (CR) uppmättes i 37% av fallen. Den sammanlagda remissionsfrekvensen i kombination med ofullständig remission (CRi), CR/Cri, var 53%. Enligt studiens tillämpade design (Simon 2-stage) uppnåddes därmed det förutbestämda primära effektmåttet avseende fullständig remission. I den fortsatta delen av fas 1/2-studien ingår elva patienter som erhåller kombinationsterapin och monitoreras avseende säkerhet och behandlingse

Karolinska Development’s portfolio company Aprea Therapeutics lead candidate drug eprenetapopt reaches primary efficacy endpoint in combination therapy of acute myeloid leukemia17.6.2021 10:25:55 CEST | Press release

STOCKHOLM, SWEDEN – June 17, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Aprea Therapeutics has reported positive outcomes in an ongoing Phase 1/2 study evaluating the efficacy of the company’s candidate drug eprenetapopt in combination with venteoclax and azacitidine in patients treated for TP53 mutated acute myeloid leukemia, AML. The results show that the primary efficacy endpoint of complete remission was reached in 37% of patients. The results are underpinned by an analysis performed on 30 evaluable patients, demonstrating complete remission in 37% of the cases. the composite response rate, i.e. CR combined with CR with incomplete hematologic recovery (CRi), CR/CRi, was 53%. The pre-defined primary efficacy endpoint concerning complete remission was thus reached in accordance with the applied study design (Simon’s 2-stage). Eleven patients remain on the study treatment and is continuously monitored on safety and efficacy para

RESULT OF RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS17.6.2021 10:10:00 CEST | Press release

RESULT OF RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS Auction date2021-06-17Loan192Coupon1.00 %ISIN-codeSE0010133207Maturity2023-03-15 Tendered volume, SEK mln800 +/- 400 Volume offered, SEK mln1,600Volume bought, SEK mln800Number of bids2Number of accepted bids1Average yield-0.064 %Lowest accepted yield-0.064 %Highest yield-0.064 %% accepted at lowest yield 100.00 Auction date2021-06-17Loan1588Coupon1.50 %ISIN-codeSE0011063015Maturity2024-03-01 Tendered volume, SEK mln2,000 +/- 1,000 Volume offered, SEK mln5,500Volume bought, SEK mln2,000Number of bids6Number of accepted bids2Average yield0.032 %Lowest accepted yield0.031 %Highest yield0.034 %% accepted at lowest yield 62.50 Auction date2021-06-17Loan151 Coupon1.00 %ISIN-codeSE0013486156Maturity2030-06-12 Tendered volume, SEK mln700 +/- 350 Volume offered, SEK mln1,600Volume bought, SEK mln700Number of bids4Number of accepted bids3Average yield0.853 %Lowest accepted yield0.851 %Highest yield0.861 %% accepted at lowest yield 71.43 Auc

Nokia accelerates Telenor and Telia joint 5G network rollout in Denmark17.6.2021 10:00:00 CEST | Press release

Press Release Nokia accelerates Telenor and Telia joint 5G network rollout in Denmark Nokia to accelerate rollout following the availability of 3.5GHz spectrum; the enhanced services will offer premium 5G speeds to customers The move builds upon Nokia’s long-standing partnership with TTN as lead supplier of 5G RAN Radio 17 June 2021 Espoo, Finland – Nokia continues to build upon its ongoing business with leading Danish mobile operators, Telenor and Telia via their joint network (TTN) accelerating the delivery of 5G services nationwide following the availability of 3.5 GHz spectrum. Nokia is the exclusive supplier of 5G RAN and will support the modernization of the shared network ensuring TTN’s three million customers have the best connectivity experiences. The availability of spectrum in the 3.5GHz band will offer incredibly fast 5G speeds to customers. The modernization deal will focus initially on Denmark’s four largest cities before expanding to cover most Danish customers during 20

Share Buyback Transaction Details June 10 – June 16, 202117.6.2021 10:00:00 CEST | Press release

Share Buyback Transaction Details June 10– June 16,2021 June 17, 2021 - Wolters Kluwer today reports that it has repurchased 68,486of its own ordinary shares in the period from June 10, 2021, up to and including June 16, 2021, for €5.6million and at an average share price of €81.21. These repurchases are part of the share buyback program announced on February 24, 2021, under which we intend to repurchase shares for up to €350 million during 2021. The cumulative amounts repurchased to date under this program are as follows: Share Buyback 2021 PeriodCumulative shares repurchased in period Total consideration (€ million)Average share price (€)2021 to date 2,697,810191.971.13 For the period starting May 6, 2021, up to and including August 2, 2021, we have engaged a third party to execute €70 million of buybacks on our behalf, within the limits of relevant laws and regulations (in particular Regulation (EU) 596/2014) and the company’s Articles of Association. Repurchased shares are added to

Board of Directors Declares Share Buyback17.6.2021 08:33:39 CEST | Press release

17 June 2021 Board of Directors Declares Share Buyback On 16 June 2021, Acron’s Board of Directors resolved that the Company repurchase its outstanding shares as envisaged by clause 2, Article 72 of the Federal Law On Joint-Stock Companies. The number of shares sought shall not exceed 4,053,400, which is 10 per cent of the authorised capital. The repurchase price shall be RUB 6,050 per share. Therefore, the buyback amount shall not exceed RUB 24.5 billion. Shareholders may apply for repurchase from 8 July 2021 through 6 August 2021 inclusive. The repurchased shares shall be paid on or before 21 August 2021. If the total number of shares tendered by the Company’s shareholders exceeds 4,053,400, shares shall be repurchased from selling shareholders on a pro rata basis. A notification of the share buyback shall be posted on the Company’s website at https://www.acron.ru/en on or before 17 June 2021. Media contacts: Sergey Dorofeev Anastasia Gromova Tatiana Smirnova Public Relations Phone:

Eurocastle Announces 2021 AGM Results and PDMR Dealing Notification17.6.2021 08:00:00 CEST | Press release

Contact: Oak Fund Services (Guernsey) Limited Company Administrator Attn: Mark Woodall Tel: +44 1481 723450 Eurocastle Announces 2021 AGM Resultsand PDMR Dealing Notification Guernsey, 17 June 2021 – Eurocastle Investment Limited (Euronext Amsterdam: ECT) (“Eurocastle” or the “Company”) today announces the results of its 2021 Annual General Meeting held yesterday, 16 June 2021. All ordinary and extraordinary business tabled before the meeting in accordance with the Notice of Annual General Meeting circulated to shareholders on 26 May 2021 was approved. A copy of this Notice is available on Eurocastle’s website at www.eurocastleinv.com under Periodic Reports and Shareholder Communications in the Investor Relations Section. In addition the Company issued 1,000 ordinary shares to each of its three independent directors as part of their in-place compensation arrangements. By reference to its obligations under Article 19 of EU Regulation 596/2014, the Company is making public the following